EDS-Fluticasone Effective in CRS Regardless of Polyp Status

A post hoc analysis of the pooled ReOpen randomized controlled trials compared outcomes with exhalation delivery system fluticasone (EDS-FLU) versus placebo in patients with chronic rhinosinusitis with nasal polyps (n=206) and without polyps (n=341) over 24 weeks. The analysis reported that both groups had substantially greater improvements with EDS-FLU versus placebo across symptom scores, smell identification testing, CT sinus opacification, exacerbation frequency, and quality-of-life measures (SNOT-22, PGIC), with treatment-by-subgroup interaction effects indicating a similar magnitude of treatment effect regardless of polyp status. Improvements were also reported to be consistent among patients who had ongoing symptoms despite recent use of standard-delivery nasal steroid sprays.

Most relevant for: Patients with chronic rhinosinusitis, both with and without nasal polyps, including those with persistent symptoms despite standard intranasal steroid spray use.

Summary written by an AI model from the source text and dated by the source's publication date. Check the original before acting on it. How MedFollow selects and summarizes updates.

Informational only. Not medical advice. Not a substitute for clinical judgment. Always consult current guidelines and your own clinical judgment.